Astellas VP-Business Development Masaki Doi: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Japanese pharma exec discusses Astellas’ global licensing strategy, the FibroGen deal, and the changing paradigm of Japanese deal flow.
Japanese pharma exec discusses Astellas’ global licensing strategy, the FibroGen deal, and the changing paradigm of Japanese deal flow.